Decima 50 mg (Decitabine Vials) 50mg

Decima 50 mg (Decitabine) is an injectable chemotherapy medication used for certain blood cancers. This 50mg vial supports treatment protocols in clinical settings. Store at room temperature away from moisture. Consult a healthcare provider for suitability.

Strength

50mg

Pack Size

Storage

Ambient

Manufacturer / TM Owner

Getwell Oncology Pvt Ltd

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Decima 50 mg (Decitabine) is prescribed for adults with myelodysplastic syndromes or acute myeloid leukemia. It works by slowing or stopping the growth of abnormal blood cells. This medication is typically administered in cycles under medical supervision. Patients often ask what is Decitabine 50 mg used for in cancer treatment.

Side Effects

Decima 50 mg may cause temporary changes in blood cell counts during therapy. Some patients report fatigue or mild nausea after administration. These effects vary by individual and are monitored closely by healthcare teams. Hydration and rest are commonly recommended during treatment.

Precautions & Warnings

Keep Decima 50 mg vials in a cool, dry place away from direct light. Handle with care to avoid contamination or breakage. Pregnant or breastfeeding individuals should discuss risks with a doctor before use. Always follow healthcare provider instructions for storage and disposal.

Avoid Interactions

Decima 50 mg may interact with other medications affecting bone marrow function. Avoid alcohol and herbal supplements unless approved by a physician. Certain vaccines may have reduced effectiveness during treatment. Discuss all current medications with your healthcare provider before starting Decitabine.

Frequently Asked Questions

Decitabine 50 mg is used to treat certain types of blood cancers like myelodysplastic syndromes and acute myeloid leukemia.

Decima 50 mg is given as an intravenous infusion by healthcare professionals in a clinical setting.

Decitabine 50 mg requires a prescription and should only be obtained through licensed pharmacies or healthcare providers.

Common effects may include fatigue, nausea, or changes in blood cell counts during treatment.

Decima 50 mg may harm an unborn baby; discuss risks with a doctor if pregnant or planning pregnancy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.